GLP-1 market shows how Americans can get lower drug prices

0
92

More than 1 in 10 U.S. adults is currently taking a GLP-1 weight-loss drug. And these medicines are getting cheaper seemingly by the day.

Since Wegovy launched, its list price has fallen from roughly $1,300 per month to between $300 and $500 per month. Similarly, Zepbound was once about $1,000 per month, but it now costs about $350. The cash prices, for patients not paying with insurance, are even lower.

These price drops are no accident. They’re the result of intense competition between rival drug companies — and strong patent protections.

OPINION: AMERICA PAYS TOO MUCH FOR MEDICINE. HERE’S WHO IS DOING SOMETHING ABOUT IT

That might sound counterintuitive. After all, critics of the pharmaceutical industry often claim that drug companies game the patent system to prevent competition and keep prices high. It’s a simple, intuitive narrative. But it’s detached from the…

Read more…

LEAVE A REPLY

Please enter your comment!
Please enter your name here